Multiple Myeloma Program

Premier Research Program

Program Leaders: Alan Gewirtz, MD and Edward Stadtmauer, MD

Since Penn's discovery of the Philadelphia Chromosome, which revolutionized cancer treatment, we've had a history of groundbreaking research.

Every day our scientists learn more about the causes of multiple myeloma as well as, better ways to detect and treat it. Penn continues to be on the cutting edge of designing novel treatments for hematologic malignancies, including multiple myeloma.

All of which can make a difference to you and your family both today and in the future.

Making History

  • Our doctors designed and oversaw trials sponsored by the National Cancer Institute and conducted by major centers nationwide. The results of these clinical trials prompted major changes in practice that reverberated throughout the nation.
  • In 1992, the Program was designated a Research Center for the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry (now know as the CIBMTR). Our faculty hold high-level administrative positions in this NIH funded international research effort.
  • In 1999, the Program was awarded the designation of Transplant Center for the National Marrow Donor Program opening the potentially lifesaving therapy of bone marrow transplant to patients without sibling donors.

Shaping the Future of Cancer Care

  • In 2001, the Transplant Program was named by the National Institutes of Health as one of the original 14 Core Clinical Transplant Centers in the NHLBI-NCI funded Blood and Marrow Transplant Clinical Network. This national network of top Transplant Centers work together to develop and conduct clinical trials in order to evaluate innovations in transplant and improve the care of patients. Penn researchers have had key roles in the administration, protocol development and conduct of clinical trials performed within the network. Penn is among the top 3 centers for enrollment on these trials.
  • Since the mid 1990's, Multiple Myeloma has become the most common indication for autologous transplant in North America. This is reflected in our clinical and research activity. Penn investigators have been in the forefront of the study of this modality in myeloma including CD34+ purging, adoptive immunotherapy with activated autologous T-cell infusions and the development of comparative trials of autologous and non-myeloablative allogeneic transplant for Multiple Myeloma.
  • In a clinical trial, the results of which were published in 2005, Penn investigators demonstrated for the first time the ability of activated T-cell infusions to re-establish immune function after transplant for Multiple Myeloma. This seminal finding has the potential to lead to tumor specific vaccine therapies for many different diseases.
  • In 2002, The Program was accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for autologous and allogeneic bone marrow and peripheral blood progenitor cell transplantation, including collection and laboratory processing. FACT accreditation is a voluntary process, which demonstrates the highest quality medical and laboratory practice for stem cell transplantation programs. The Program was the first adult center in the Delaware Valley to show such distinction in both quality of patient care and research. Our continued excellence was recognized by renewed accreditation in 2005.
  • In 2002, the Abramson Cancer Center was one of three recipients worldwide of the prestigious Specialized Center of Research Award from the Leukemia and Lymphoma Society to support ongoing research to design the next generation therapies for leukemia and lymphoma.

As one of the nation's largest cancer research centers our investigators benefit each day from collaborations and interactions with over 400 scientists and physicians involved in the Abramson Cancer Center.